Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTV01C Booster in Previously Vaccinated or Recovered Adults
NCT05238454Phase 2Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Mar 2022
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of sctv01c in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by Sinocelltech Group Limited. Primary endpoints: Geometric Mean Titer (GMT) of neutralizing antibodies to Delta (B.1.617.2) variant at Day 28, Geometric Mean Titer (GMT) of neutralizing antibodies to Omicron (B.1.1.529) variant at Day 28 and 2 more. Status: unknown.
02
Drugs
sctv01c
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05238454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238454.